Eventide Asset Management

Beta Bionics is a biotechnology company focused on developing advanced solutions for diabetes management. Its flagship product, the iLet Bionic Pancreas System, is an integrated device designed to alleviate the burden of diabetes care. This system encompasses a dual-chamber infusion pump that delivers insulin and glucagon with precision and accuracy, autonomously calculating and administering doses to help patients maintain optimal blood sugar levels. The iLet has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal, and it incorporates Zealand Pharma’s dasiglucagon, which is known for its stability in a ready-to-use aqueous solution. Through these innovations, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

PreciseDx is a specialized company focused on cancer risk stratification, providing patient-specific risk assessments through the analysis of morphological features. By leveraging artificial intelligence and its proprietary Morphology Feature Array™, PreciseDx develops disease-specific assays that enhance the understanding of a patient's risk profile and potential outcomes. This innovative approach allows clinical teams to gain valuable insights and actionable intelligence, facilitating more personalized treatment decisions. The company's expertise spans clinical modeling, patient phenotyping, image analysis, and the application of big data in real-world scenarios, ultimately aiming to improve patient outcomes and quality of life in cancer care and other diseases.

Kestra Medical Technologies, Inc. is a company that specializes in developing and manufacturing wearable medical devices aimed at monitoring and managing acute medical conditions. Founded in 2014 and headquartered in Kirkland, Washington, the company offers solutions that enable the collection, communication, and storage of patient performance data, facilitating both real-time and retrospective analysis. Among its key products are wearable cardioverter defibrillators designed to prevent sudden cardiac death and aid in the recovery of at-risk cardiac patients. By focusing on intuitive and mobile diagnostic and therapeutic technologies, Kestra Medical Technologies strives to enhance patient care and support healthcare teams in effectively managing patient health.

Celcuity Inc. is a clinical-stage biotechnology company based in Minneapolis, Minnesota, focusing on cancer diagnosis and treatment. The company utilizes its CELsignia diagnostic platform, which analyzes living tumor cells to identify specific cellular processes that drive individual cancers. This innovative approach enables the discovery of new cancer sub-types that traditional molecular diagnostics may miss. Celcuity is developing diagnostic tests, including the CELsignia HSF test for HER2-negative breast cancer and the CELsignia MP test for various cancers, such as breast, lung, colon, ovarian, kidney, and bladder. By translating these discoveries into companion diagnostics, Celcuity aims to enhance therapeutic options for cancer patients and improve treatment outcomes, while also aiding pharmaceutical companies in defining targeted therapy patient populations more accurately. Founded in 2011, Celcuity is committed to advancing oncology through precise diagnostic and therapeutic innovations.

Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.

Sudo Biosciences is a biopharmaceutical company focused on designing and developing innovative medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain. This domain plays a vital role in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. Sudo Biosciences has a pipeline of next-generation TYK2 inhibitors, including a candidate aimed at treating multiple sclerosis and neurodegenerative diseases characterized by neuroinflammation, as well as a topical treatment for immune-mediated dermatologic diseases. The company's mission is to provide effective therapies for patients at competitive costs, thereby transforming their lives and addressing unmet medical needs.

Sudo Biosciences is a biopharmaceutical company focused on designing and developing innovative medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain. This domain plays a vital role in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. Sudo Biosciences has a pipeline of next-generation TYK2 inhibitors, including a candidate aimed at treating multiple sclerosis and neurodegenerative diseases characterized by neuroinflammation, as well as a topical treatment for immune-mediated dermatologic diseases. The company's mission is to provide effective therapies for patients at competitive costs, thereby transforming their lives and addressing unmet medical needs.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Beta Bionics is a biotechnology company focused on developing advanced solutions for diabetes management. Its flagship product, the iLet Bionic Pancreas System, is an integrated device designed to alleviate the burden of diabetes care. This system encompasses a dual-chamber infusion pump that delivers insulin and glucagon with precision and accuracy, autonomously calculating and administering doses to help patients maintain optimal blood sugar levels. The iLet has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal, and it incorporates Zealand Pharma’s dasiglucagon, which is known for its stability in a ready-to-use aqueous solution. Through these innovations, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Flare Therapeutics is a biotechnology company dedicated to developing small molecule medicines through a novel approach to understanding transcription factors. By identifying 'switch sites,' which are druggable regions crucial for regulating transcription factors, Flare aims to target mutations that lead to various diseases. The company has rapidly advanced its drug discovery efforts, creating an emerging pipeline of programs initially focused on precision oncology. Additionally, Flare's innovative platform holds promise for addressing conditions in neurology, rare genetic disorders, immunology, and inflammation, ultimately enabling medical professionals to transform treatment strategies for patients.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Beta Bionics is a biotechnology company focused on developing advanced solutions for diabetes management. Its flagship product, the iLet Bionic Pancreas System, is an integrated device designed to alleviate the burden of diabetes care. This system encompasses a dual-chamber infusion pump that delivers insulin and glucagon with precision and accuracy, autonomously calculating and administering doses to help patients maintain optimal blood sugar levels. The iLet has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal, and it incorporates Zealand Pharma’s dasiglucagon, which is known for its stability in a ready-to-use aqueous solution. Through these innovations, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Shoreline Biosciences, Inc. is a biotechnology company based in La Jolla, California, founded in 2020. The company specializes in developing cell-based immunotherapies aimed at treating seriously ill patients. Shoreline's proprietary technology platform leverages advanced methods in induced pluripotent stem cell (iPSC) differentiation and genetic programming, specifically targeting the IL-15/CISH pathway. This approach enhances the metabolic fitness and persistence of engineered natural killer (NK) cells, improving their anti-cancer activity. Shoreline's focus includes creating clinically effective immunotherapies using iPSC-derived NK cells and macrophages, providing innovative and cost-effective treatment options for oncology and other serious health conditions.

Roivant Sciences is a biopharmaceutical company dedicated to advancing the development of innovative late-stage drug candidates and enhancing healthcare delivery. The company aims to expedite the process of bringing new medicines to patients while reducing associated costs, thereby benefiting the healthcare system. Roivant achieves this by creating specialized entities known as "Vants," which are agile biotech and healthcare technology companies that leverage unique talent sourcing and incentive alignment strategies. In addition to its focus on biopharmaceuticals, Roivant incubates discovery-stage companies and health technology startups that complement its core business. Among its commercial-stage drug candidates is VTAMA, a treatment for plaque psoriasis in adults, along with several other candidates, including Batoclimab, IMVT-1402, Brepocitinib, and Namilumab, which are at various stages of development.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Kojin Therapeutics, founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, focuses on advancing a drug discovery platform that links complex cell states to established biochemical processes, specifically ferroptosis, which involves iron-dependent cell death. This innovative approach enables the development of targeted therapies for a wide range of challenging diseases that are often difficult to treat. The company's biology platform aims to identify disease-specific targets, ensuring that patients receive effective treatments tailored to their specific conditions. Kojin Therapeutics is supported by a diverse group of investors, including Polaris Partners, Newpath Partners, and AbbVie, among others.

Flare Therapeutics is a biotechnology company dedicated to developing small molecule medicines through a novel approach to understanding transcription factors. By identifying 'switch sites,' which are druggable regions crucial for regulating transcription factors, Flare aims to target mutations that lead to various diseases. The company has rapidly advanced its drug discovery efforts, creating an emerging pipeline of programs initially focused on precision oncology. Additionally, Flare's innovative platform holds promise for addressing conditions in neurology, rare genetic disorders, immunology, and inflammation, ultimately enabling medical professionals to transform treatment strategies for patients.

Arch Oncology, Inc. is an immuno-oncology company focused on discovering and developing antibody therapeutics for the treatment of solid tumors and hematologic cancers. Founded in 2006 and headquartered in Brisbane, California, with a scientific research laboratory in St. Louis, Missouri, the company is known for its innovative approach to cancer treatment. Arch Oncology specializes in anti-CD47 antibodies, which represent a new class of checkpoint inhibitors that engage both the adaptive and innate immune responses. These functionally diverse antibodies not only inhibit immune checkpoints but also selectively target and kill tumor cells, providing patients with new therapeutic options in the fight against cancer.

Biosplice Therapeutics is a company focused on medical research and development in tissue-level regeneration. Its platform, which originated from small molecule-based modulation of the Wnt signaling pathway, is designed to create therapeutics for a variety of degenerative diseases, including osteoarthritis and certain cancers. By discovering new biological targets and processes, Biosplice Therapeutics aims to develop innovative small molecule drugs that could provide curative therapies for multiple conditions. The company's objective is to enhance patient health through a comprehensive technology platform dedicated to modulating regenerative pathways.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Prometheus Biosciences, established in 1995 and headquartered in San Diego, California, specializes in developing and commercializing innovative pharmaceutical and diagnostic products. The company's portfolio includes tests that enable physicians to provide personalized patient care, such as monitoring drug and anti-drug antibody levels, diagnosing and prognosticating inflammatory bowel disease (IBD), and detecting celiac disease and lactose intolerance. Prometheus also offers therapeutic products like Entocort EC for treating Crohn's disease and has agreements to develop and market other drugs. The company's commitment to innovation positions it as a leader in precision healthcare, particularly in gastroenterology.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Talaris Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies aimed at eliminating chronic immunosuppression for organ transplant recipients. The company's leading product, FCR001, is designed to enable living donor kidney transplant recipients to discontinue all chronic immunosuppression therapy within twelve months post-transplant. In addition to its applications in organ transplantation, Talaris’s technology facilitates the safe use of hematopoietic stem cells from unmatched and unrelated donors for bone marrow transplants, reducing the associated toxicity and risks of traditional methods. Founded in 1988 and originally named Regenerex, Inc., Talaris Therapeutics rebranded in March 2019. The company is headquartered in Louisville, Kentucky, with an additional office in Wellesley, Massachusetts.

Casma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative therapeutic strategies centered on the natural cellular process of autophagy. Founded in 2017, the company aims to enhance autophagy to improve the clearance of unwanted proteins, organelles, and pathogens, thereby addressing significant medical challenges. Casma Therapeutics is advancing preclinical programs targeting various conditions, including muscle disorders, liver disease, inflammatory disorders, and neurodegenerative diseases. By harnessing and manipulating the autophagy system, the company seeks to arrest or reverse disease progression, ultimately enabling physicians to meet unmet medical needs and provide effective treatments for patients with serious health issues.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders marked by neuronal imbalance. Established in 2015 and headquartered in Cambridge, Massachusetts, the company leverages genetic insights to create innovative treatments for neurological and psychiatric conditions. Its leading product candidates include PRAX-114, an allosteric modulator targeting GABAA receptors, currently undergoing Phase IIa trials for major depressive disorder and perimenopausal depression, and PRAX-944, a selective inhibitor of T-type calcium channels in Phase IIa trials for essential tremor. Additionally, Praxis is advancing PRAX-562, a sodium current blocker in Phase I trials for severe pediatric epilepsy and adult cephalgia, along with PRAX-222, an antisense oligonucleotide aimed at treating patients with SCN2A epilepsy, and a program focused on KCNT1-related epilepsy. The company has established collaborations and licensing agreements with various organizations to enhance its research and development efforts.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

Freeline Therapeutics, established in 2015 and based in Stevenage, UK, is a clinical-stage biotechnology company specializing in the development of systemic adeno-associated virus (AAV) vector-mediated gene therapies. The company focuses on treating inherited, debilitating diseases by delivering functional copies of therapeutic genes into human liver cells, enabling the production of functional proteins in the bloodstream. Freeline's pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, and FLT201 for Gaucher disease Type 1, all in various stages of clinical trials. Additionally, the company offers expertise in CMC process development, analytics, and AAV technologies.

Goldfinch Bio, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, dedicated to discovering and developing precision therapies for patients with kidney diseases. The company focuses on conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Key product candidates include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio integrates advancements in kidney genetics and biology through its Kidney Genome Atlas, a genomic registry that aids in identifying new disease targets and biomarkers. Additionally, the company employs stem cell science to create human organoid models, which facilitate the validation of novel therapeutic targets. Goldfinch Bio has established a strategic collaboration with Gilead Sciences to further enhance its research and development efforts. Founded in 2016, Goldfinch Bio aims to transform the treatment landscape for progressive kidney disease.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing innovative therapies for fibrotic diseases. Its lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both indications and is currently undergoing Phase 2a clinical trials. The company is also developing PLN-1474, a small-molecule selective inhibitor of avß1, for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, which is in Phase 1 trials. Founded in 2015, Pliant Therapeutics is also advancing preclinical programs aimed at addressing oncology and muscular dystrophies.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in New York that focuses on developing small molecule therapeutics for cancer treatment. Established in 2014, the company employs an integrated discovery engine to identify and develop new chemical entities targeting critical biological pathways in various cancers. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader currently undergoing Phase I/II clinical trials for advanced or metastatic breast cancer. Additionally, Zentalis is advancing several other candidates, including ZN-c3, an inhibitor of the WEE1 protein for advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor for advanced non-small cell lung cancer, all of which are in various stages of clinical development.

Beta Bionics is a biotechnology company focused on developing advanced solutions for diabetes management. Its flagship product, the iLet Bionic Pancreas System, is an integrated device designed to alleviate the burden of diabetes care. This system encompasses a dual-chamber infusion pump that delivers insulin and glucagon with precision and accuracy, autonomously calculating and administering doses to help patients maintain optimal blood sugar levels. The iLet has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal, and it incorporates Zealand Pharma’s dasiglucagon, which is known for its stability in a ready-to-use aqueous solution. Through these innovations, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that incorporates a proprietary dry-powder formulation of dihydroergotamine mesylate. Designed for self-administration, STS101 utilizes a pre-filled, single-use nasal delivery device, enhancing patient convenience and accessibility. The product is currently undergoing Phase III clinical trials, marking a significant step in its development. Founded in 2016, Satsuma is headquartered in South San Francisco, California.

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, that specializes in developing innovative therapies for neuropsychiatric disorders and pain management. The company is advancing its lead product candidate, KarXT, an oral modulator that has completed a Phase II clinical trial for acute psychosis in schizophrenia and is undergoing Phase Ib trials for various central nervous system disorders, including the cognitive and negative symptoms associated with schizophrenia, Alzheimer's disease, and dementia-related psychosis. Karuna Therapeutics is also actively developing a pipeline of muscarinic-targeted drug candidates to address unmet medical needs in these challenging areas. Founded in 2009, the company has established partnerships and licensing agreements to support its drug discovery efforts and to enhance its research capabilities.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, dedicated to developing innovative medicines for patients with cancer and other serious conditions. The company focuses on targeting HIF-2a, a transcription factor previously considered difficult to address with small molecules. Its lead drug candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma, and it is being evaluated in various settings, including in patients with von Hippel-Lindau disease-associated renal cell carcinoma and in combination with cabozantinib. Additionally, Peloton is advancing PT2567, another oral HIF-2a inhibitor in preclinical development for non-oncology indications such as pulmonary arterial hypertension. Founded in 2010 and previously known as Damascus Pharmaceutics, Peloton Therapeutics aims to leverage its scientific expertise and collaborations to become a leading biotech company in the region.

Beta Bionics is a biotechnology company focused on developing advanced solutions for diabetes management. Its flagship product, the iLet Bionic Pancreas System, is an integrated device designed to alleviate the burden of diabetes care. This system encompasses a dual-chamber infusion pump that delivers insulin and glucagon with precision and accuracy, autonomously calculating and administering doses to help patients maintain optimal blood sugar levels. The iLet has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal, and it incorporates Zealand Pharma’s dasiglucagon, which is known for its stability in a ready-to-use aqueous solution. Through these innovations, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing innovative therapies for fibrotic diseases. Its lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both indications and is currently undergoing Phase 2a clinical trials. The company is also developing PLN-1474, a small-molecule selective inhibitor of avß1, for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, which is in Phase 1 trials. Founded in 2015, Pliant Therapeutics is also advancing preclinical programs aimed at addressing oncology and muscular dystrophies.

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on advancing stem cell transplantation and related therapies. Founded in 2015, the company aims to enhance the patient experience in transplant medicine by developing innovative treatments that make stem cell transplants safer and more accessible. Its pipeline includes several key candidates, such as C100, C200, and C300 targeted antibody-drug conjugates designed for transplant conditioning; MGTA-145, a stem cell mobilization product; and MGTA-456, an allogeneic stem cell therapy. Additionally, Magenta is exploring E478, a small molecule aimed at expanding gene-modified stem cells, and G100, an antibody-drug conjugate to mitigate acute graft-versus-host disease. The company has established research collaborations with other biotechnology firms to further investigate the potential of its therapies in treating blood cancers, genetic disorders, and autoimmune diseases, ultimately striving to transform stem cell transplantation from a last-resort option into a more viable and effective treatment for patients.

Entasis Therapeutics is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. It focuses on developing novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria. The company's pipeline includes Sulbactam-durlobactam (SUL-DUR) for Acinetobacter infections, Zoliflodacin for gonorrhea, ETX0282CPDP for urinary tract infections, and ETX0462 for multidrug-resistant Gram-negative infections. Entasis has collaboration agreements with Zai Lab for the development of SUL-DUR.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing products aimed at addressing the challenges associated with pain management and the abuse of prescription drugs. The company utilizes its proprietary DETERx platform technology to create abuse-deterrent formulations that maintain the extended-release and safety profiles of medications, making them less susceptible to misuse through methods such as chewing or injecting. Collegium's primary products include Xtampza ER, an abuse-deterrent extended-release formulation of oxycodone, and Nucynta, which encompasses both extended-release and immediate-release formulations of tapentadol for managing severe pain. Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium focuses on delivering innovative solutions that enhance patient safety while effectively treating chronic pain conditions.